FR2733913B1 - Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant - Google Patents

Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant

Info

Publication number
FR2733913B1
FR2733913B1 FR9505468A FR9505468A FR2733913B1 FR 2733913 B1 FR2733913 B1 FR 2733913B1 FR 9505468 A FR9505468 A FR 9505468A FR 9505468 A FR9505468 A FR 9505468A FR 2733913 B1 FR2733913 B1 FR 2733913B1
Authority
FR
France
Prior art keywords
medicament
pharmaceutical compositions
dna sequence
compositions containing
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9505468A
Other languages
English (en)
Other versions
FR2733913A1 (fr
Inventor
Jean Paul Escande
Mahmood Salman El
Claire Lugassy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9478796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2733913(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR9505468A priority Critical patent/FR2733913B1/fr
Priority to AU58252/96A priority patent/AU5825296A/en
Priority to PCT/FR1996/000691 priority patent/WO1996035791A1/fr
Publication of FR2733913A1 publication Critical patent/FR2733913A1/fr
Application granted granted Critical
Publication of FR2733913B1 publication Critical patent/FR2733913B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
FR9505468A 1995-05-09 1995-05-09 Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant Expired - Fee Related FR2733913B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR9505468A FR2733913B1 (fr) 1995-05-09 1995-05-09 Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
AU58252/96A AU5825296A (en) 1995-05-09 1996-05-09 Dna sequence, coding for a ribozyme, useful as a drug, and p harmaceutical compositions containing same
PCT/FR1996/000691 WO1996035791A1 (fr) 1995-05-09 1996-05-09 Sequence d'adn codant pour un ribozyme a titre de medicament, et compositions pharmaceutiques la contenant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9505468A FR2733913B1 (fr) 1995-05-09 1995-05-09 Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant

Publications (2)

Publication Number Publication Date
FR2733913A1 FR2733913A1 (fr) 1996-11-15
FR2733913B1 true FR2733913B1 (fr) 1997-08-01

Family

ID=9478796

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9505468A Expired - Fee Related FR2733913B1 (fr) 1995-05-09 1995-05-09 Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant

Country Status (3)

Country Link
AU (1) AU5825296A (fr)
FR (1) FR2733913B1 (fr)
WO (1) WO1996035791A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2324421A1 (fr) * 1998-03-27 1999-10-07 Ribozyme Pharmaceuticals, Inc. Procede et reactifs pour le traitement de maladies ou d'affections associees a des molecules impliquees dans les reactions angiogeniques
FR2826010B1 (fr) 2001-06-14 2005-02-25 Mahmood Salman Al Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par les cellules endotheliales
US9682144B2 (en) 2011-06-30 2017-06-20 Gene Signal International, Sa Composition comprising inhibitors of IRS-1 and of VEGF
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide

Also Published As

Publication number Publication date
WO1996035791A1 (fr) 1996-11-14
AU5825296A (en) 1996-11-29
FR2733913A1 (fr) 1996-11-15

Similar Documents

Publication Publication Date Title
DZ2461A1 (fr) Dérivés d'arylkylamines nouveaux et composition pharmaceutiques les contenant.
DZ1916A1 (fr) Composés nouveaux et compostions pharmaceutiques les contenant.
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
DZ2086A1 (fr) Benzylaminopipéridines substituées et compositionspharmaceutiques les contenant.
MA26685A1 (fr) Derives d'azetidine leur preparation et les medicaments les contenant
DK0754061T3 (da) Ny oral farmaceutisk doseringsform
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
FI973278A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
FI973279A (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
GR3031526T3 (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing same
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
FR2774687B1 (fr) Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
FR2737721B1 (fr) Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
MA26567A1 (fr) Trifluoromethylethers cycliques a fonction piperidinylaminomethule, procede pour leur preparation et compositions pharmaceutiques les contenant
HUP9801880A3 (en) Novel cryptophycins, their use and pharmaceutical compositions containing them
IL117878A0 (en) Taxoids, their preparation and pharmaceutical compositions containing them
FR2730995B1 (fr) Composes bi-aromatiques derives d'amide, compositions pharmaceutiques et cosmetiques les contenant et utilisations
IL117989A (en) N-(1-(3,5-bisfluoromethylbenzoyl)-2- benzyl-piperidin-4-YL)-4-oxo-4H-1- benzopyran-2 carboxamides their preparation and pharmaceutical compositions comprising them
HUP9900317A3 (en) Pharmaceutical composition useful for nucleic acid transfection, and use thereof
IL117760A0 (en) Taxoids, their preparation and pharmaceutical compositions containing them
HUP9901349A3 (en) Oxazolidinone derivatives, their preparation and pharmaceutical compositions containing these compounds
FR2733913B1 (fr) Sequence d'adn a titre de medicament, et compositions pharmaceutiques en contenant
MA26745A1 (fr) Diphosphate d'un derive de 9-deoxo-9a-aza-9a-homoerythromycine substituee en 4", son procede de preparation et composition pharmaceutique le contenant

Legal Events

Date Code Title Description
CA Change of address
TP Transmission of property
ST Notification of lapse